The arthritic Paradigm

Paradigm Biopharma (ASX: PAR) listed on the ASX in August 2015. The company focuses on repurposing pentosan polysulphate sodium (PPS) and CEO Paul Rennie tells Alan Kohler Paradigm has an exclusive deal with the only maker of pentosan for arthritic use.

Become a TCI Community Member Now

Stay up to date and make better informed decisions.
Get access to all this exclusive content and so much more every week!

  • $1 for the first month
  • $25/month membership
  • Cancel anytime, no lock in contract
  • Access to Private Facebook group
  • Smartphone App (coming soon)